HIGHLIGHTS
- who: Matteo Molica et al. from the Department of Biomedicina and Prevenzione, Tor Vergata University, Rome, Italy have published the research work: CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML, in the Journal: Cancers 2022, 14, 2843. https:// of 29/04/2022
SUMMARY
Acute myeloid leukemia (AML) is a hematopoietic progenitor cell clonal disease in which a population of leukemic stem_cells drives the proliferation of aberrant myeloid precursor cells (blasts) that become unable to differentiate. In developed countries, more than half of newly diagnosed AML . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.